JP2018527327A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527327A5
JP2018527327A5 JP2018504124A JP2018504124A JP2018527327A5 JP 2018527327 A5 JP2018527327 A5 JP 2018527327A5 JP 2018504124 A JP2018504124 A JP 2018504124A JP 2018504124 A JP2018504124 A JP 2018504124A JP 2018527327 A5 JP2018527327 A5 JP 2018527327A5
Authority
JP
Japan
Prior art keywords
hcab
antigen binding
binding specificity
ang
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018504124A
Other languages
English (en)
Japanese (ja)
Other versions
JP6916776B2 (ja
JP2018527327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044838 external-priority patent/WO2017020001A2/en
Publication of JP2018527327A publication Critical patent/JP2018527327A/ja
Publication of JP2018527327A5 publication Critical patent/JP2018527327A5/ja
Application granted granted Critical
Publication of JP6916776B2 publication Critical patent/JP6916776B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018504124A 2015-07-29 2016-07-29 Ａｎｇ−２に対する重鎖のみ抗体 Expired - Fee Related JP6916776B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562198518P 2015-07-29 2015-07-29
US62/198,518 2015-07-29
US201562205185P 2015-08-14 2015-08-14
US62/205,185 2015-08-14
PCT/US2016/044838 WO2017020001A2 (en) 2015-07-29 2016-07-29 Heavy chain only antibodies to ang-2

Publications (3)

Publication Number Publication Date
JP2018527327A JP2018527327A (ja) 2018-09-20
JP2018527327A5 true JP2018527327A5 (enExample) 2019-07-18
JP6916776B2 JP6916776B2 (ja) 2021-08-11

Family

ID=56610025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504124A Expired - Fee Related JP6916776B2 (ja) 2015-07-29 2016-07-29 Ａｎｇ−２に対する重鎖のみ抗体

Country Status (13)

Country Link
US (3) US10266589B2 (enExample)
EP (2) EP3792279A3 (enExample)
JP (1) JP6916776B2 (enExample)
CN (1) CN107849126B (enExample)
AU (2) AU2016298398A1 (enExample)
BR (1) BR112018001762A2 (enExample)
CA (1) CA2992660A1 (enExample)
DK (1) DK3328886T3 (enExample)
ES (1) ES2828694T3 (enExample)
HU (1) HUE051165T2 (enExample)
PL (1) PL3328886T3 (enExample)
RU (1) RU2749674C2 (enExample)
WO (1) WO2017020001A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN107849126B (zh) * 2015-07-29 2022-04-08 阿勒根公司 仅有重链的抗ang-2抗体
AU2016307943A1 (en) * 2015-08-14 2018-02-15 Allergan, Inc. Heavy chain only antibodies to PDGF
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP4240832A4 (en) * 2020-11-04 2025-01-01 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
PL223153B1 (pl) 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US7691365B2 (en) * 2004-09-28 2010-04-06 Aprogen, Inc. Methods of using chimeric coiled coil molecule to treat ischemic disease
HRP20110859T1 (hr) * 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
BRPI0706750A2 (pt) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102307902B (zh) * 2008-12-10 2016-02-24 埃博灵克斯股份有限公司 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2865464C (en) * 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Ang2-binding molecules
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SG11201408538PA (en) * 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013343099A1 (en) 2012-11-09 2015-05-14 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9902767B2 (en) * 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) * 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
AU2015345322A1 (en) * 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-PDGF-B antibodies and methods of use
CN107849126B (zh) * 2015-07-29 2022-04-08 阿勒根公司 仅有重链的抗ang-2抗体
AU2016307943A1 (en) * 2015-08-14 2018-02-15 Allergan, Inc. Heavy chain only antibodies to PDGF

Similar Documents

Publication Publication Date Title
JP2018527327A5 (enExample)
JP2016504416A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2010528047A5 (enExample)
RU2015121755A (ru) Антагонисты ил-6 и их применение
JP2020062036A5 (enExample)
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2017536414A5 (enExample)
JP2020114218A5 (enExample)
RU2488594C2 (ru) Гуманизированные антитела против фактора d и их применения
JP2014532072A5 (enExample)
RU2009149385A (ru) АНТИТЕЛА ПРОТИВ С3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
JP2019515027A5 (enExample)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
RU2008138399A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (НРТРβ), И ИХ ИСПОЛЬЗОВАНИЕ
JP2017534646A5 (enExample)
JP2013528607A5 (enExample)
JP2018510617A5 (enExample)
JP2014509510A5 (enExample)
JP2012165745A5 (enExample)
JP2017534645A5 (enExample)
RU2017120360A (ru) Биспецифические антитела и способы их применения в офтальмологии
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2017537896A5 (enExample)